Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 1, 2012-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 12, 2012-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that for the period of September 12, 2012 to March 11, 2013 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the

LabCorp is Scheduled to Present at the Morgan Stanley Global Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 4, 2012-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that David P. King , Chairman and Chief Executive Officer, is scheduled to speak at the Morgan Stanley Global Healthcare Conference in New York, NY .

LabCorp Prices $500 Million in 2.20% Senior Notes Due 2017 and $500 Million in 3.75% Senior Notes Due 2022

BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 20, 2012-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that it has priced its offering of $1 billion in senior notes. The offering consists of two tranches: $500 million aggregate principal amount of 2.20% Senior

LabCorp Announces Proposed Sale of Senior Notes

BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 20, 2012-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that it plans to offer, subject to market and other conditions, senior notes that are expected to be issued in two tranches with maturities of 5 and 10 years (the

LabCorp Commends CDC for Revised HCV Testing Guidelines; Leading HCV Tests Available Through Monogram Biosciences, part of LabCorp’s Specialty Testing Group

BURLINGTON, N.C. -- (BUSINESS WIRE) -- Aug. 17, 2012 -- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announces its support for guidance issued today by the Centers for Disease Control and Prevention (CDC) that recommends hepatitis C virus (HCV) testing in all people born

LabCorp Completes and Publishes a Clinical Study for the Development and Validation of a PCR Assay for the Diagnosis of Bacterial Vaginosis

BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 7, 2012-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the publication in the July 2012 Journal of Clinical Microbiology of a clinical study that supports validation of a new clinical diagnostic test for bacterial

LabCorp Addresses Rumors of Buyout

BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 1, 2012-- Laboratory Corporation of America® Holdings (NYSE: LH) today announced it is aware of the recent reports regarding possible plans by private equity firms to seek to effect a leveraged buyout of the Company.

LabCorp Completes Acquisition of MEDTOX

BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 1, 2012-- Laboratory Corporation of America® Holdings (NYSE: LH) today announced the completion of its acquisition of MEDTOX Scientific, Inc. (NASDAQ: MTOX), effective July 31, 2012 . At a special meeting held on July 31, 2012 , MEDTOX’s stockholders

Laboratory Corporation of America® Holdings Announces 2012 Second Quarter Results

LabCorp Reports Q2 Diluted EPS of $1.56 and Adjusted EPS Excluding Amortization of $1.77 , up 7.9% BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 19, 2012-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced results for the quarter ended June 30, 2012 .